Corporate Overview
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet
HTMLInvestor Kit
HRTX (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$32.68
Change (%) Stock is Down 1.21 (0.00%)
Volume289,907
Data as of 07/29/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Presentation
Download Documentation Corporate Presentation, July 2015

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biotechnology company developing products using its proprietary technology and innovative efforts to develop products to address unmet medical needs. The Company's Biochronomer® polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. The Company's lead product, SUSTOL® (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.

Recent NewsMore >>
DateTitle 
07/23/15Heron Therapeutics Initiates Second Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative Pain
- HTX-011 to be evaluated in approximately 60 patients undergoing inguinal hernia repair REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 23, 2015-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced that it has initiated a second Phase 2 clinical trial of HTX-011. HTX-011, which utilizes Heron’s prop... 
Printer Friendly Version
07/20/15Heron Therapeutics Resubmits SUSTOL® New Drug Application to FDA
-SUSTOL has potential to be the first 5-HT3 antagonist approved for delayed nausea and vomiting associated with highly emetogenic chemotherapy REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 20, 2015-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced that it has resubmitted its New Drug Application... 
Printer Friendly Version
06/16/15Heron Therapeutics Initiates Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative Pain
- FDA Clears IND for HTX-011 REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 16, 2015-- Heron Therapeutics, Inc. (NASDAQ: HRTX) announced today that it has initiated a Phase 2 clinical trial of HTX-011, the Company’s lead product candidate for the prevention of post-operative pain, following clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for HTX-011. HTX-011, which utilizes Heron’s prop... 
Printer Friendly Version
06/15/15Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 15, 2015-- Heron Therapeutics, Inc. (NASDAQ: HRTX), today announced closing of its underwritten public offering of 5,520,000 shares of common stock, including 720,000 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriters, at a public offering price of $24.75 per share. The gross offering size was approximately $136.6 million before deducting ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.


View: Mobile | Desktop